Department of Neurology, Medical University Innsbruck, Austria.
Department of Neurology, Medical University Innsbruck, Austria.
Neuropharmacology. 2020 Jul;171:108085. doi: 10.1016/j.neuropharm.2020.108085. Epub 2020 Apr 13.
To date, despite numerous clinical trials, no intervention has been demonstrated to modify the progression of Parkinson's disease (PD). However, over the past decades encouraging progress has been made towards a better understanding of molecular pathways relevant for the neurodegenerative process in PD. This is also based on new insights into the genetic architecture of the disease, revealing multiple novel targets for potentially disease-modifying interventions. Important achievements have also been made in the field of risk markers and combinations thereof, in the form of risk algorithms, will hopefully soon provide the possibility to identify affected individuals at yet prediagnostic or prodromal stages of the illness. Such phases of the disease would provide an ideal window for neuroprotection trials. Taken together, these developments offer hope that a breakthrough towards modifying the course of PD might be reached. In this article we summarize various approaches currently pursued in this quest. This article is part of the special issue entitled 'The Quest for Disease-Modifying Therapies for Neurodegenerative Disorders'.
迄今为止，尽管进行了大量临床试验，但尚无干预措施被证明可改变帕金森病 (PD) 的进展。然而，在过去的几十年中，人们对与 PD 神经退行性过程相关的分子途径有了更深入的了解，这方面也取得了令人鼓舞的进展。这也是基于对疾病遗传结构的新认识，揭示了多个潜在的可改变疾病的干预靶点。在风险标志物及其组合领域也取得了重要进展，以风险算法的形式，有望很快能够在疾病的 yet 诊断前或前驱期识别出受影响的个体。疾病的这些阶段将为神经保护试验提供一个理想的窗口期。总之，这些发展为改变 PD 病程带来了希望。在本文中，我们总结了目前在这一探索中采用的各种方法。本文是专题“寻找神经退行性疾病的治疗方法”的一部分。
